[Sentinel lymphonodectomy -- new surgical standard for the evaluation of the axilla:an overview. Part 1].
Complete axillary dissection is still integral component of breast cancer treatment, but significant morbidity is associated with this procedure. Sentinel lymphonodectomy can replace complete axillary dissection in selected cases and can significantly reduce morbidity. Sentinel lymphonodectomy has become a new surgical standard and should be offered to all patients with unicentric tumors of less than 3 cm in diameter. Open questions concern the localization of the market injection, the significance of detecting and extirpation of extra-axillary lymph nodes, the applicability of the method to multicentric tumors, after neoadjuvant chemotherapy, after previous breast biopsy, to DCIS and tumors of more than 3 cm in diameter. Clinical trials have to establish whether axillary dissection after finding a micrometastasis in the sentinel node is necessary or not.
Rageth
Christoph J
CJ
Brust-Zentrum, Zurich, Schweiz. c.rageth@brust-zentrum.ch
Scholl
Beatrix
B
Sarasin
Eliane
E
Saurenmann
Elisabeth
E
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001365:Axilla / Q000601:surgery; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D005260:Female; D006801:Humans; D008197:Lymph Node Excision / Q000592:standards; D008207:Lymphatic Metastasis / Q000473:pathology; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D017410:Practice Guidelines as Topic; D011237:Predictive Value of Tests; D011379:Prognosis; D011785:Quality Assurance, Health Care / Q000592:standards; D021701:Sentinel Lymph Node Biopsy / Q000592:standards*
D000970:Antineoplastic Agents